

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

POSITIVE PROFIT ALERT

This announcement is made by Winteam Pharmaceutical Group Limited (the “Company”, and together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors (the “Board”) of the Company wishes to inform shareholders of the Company (the “Shareholders”) and potential investors that based on the preliminary assessment by the Group’s management of the unaudited management accounts of the Group for the six months ended 30 June 2012, the Group is expected to record a significant increase in net profit for the six months ended 30 June 2012 as compared to that of the six months ended 30 June 2011.

Based on information currently available, the profit increase is expected to be mainly attributable to (i) the steady growth in sales of the Group; (ii) effective cost control over sales and marketing expenses; and (iii) the decrease in cost of raw materials, as the result of the decline in price of Chinese herbal medicines commonly used by the Group.

As the Company is still in the process of finalising its financial results for the six months ended 30 June 2012, the information contained herein is only based on the preliminary assessment by the Group’s management of the unaudited management accounts of the Group and information currently available, which have not been audited or reviewed by the auditors of the Company. It is expected that the unaudited interim results of the Group for the six months ended 30 June 2012 will be announced on 30 August 2012.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Winteam Pharmaceutical Group Limited
XU Tiefeng
Chairman

Hong Kong, 10 July 2012

As at the date of this announcement, the Board comprises eight Directors, of which Mr. XU Tiefeng, Mr. YANG Bin and Mr. SITU Min are executive Directors; Mr. DU Richeng is a non-executive Director; and Mr. LO Wing Yat, Mr. PANG Fu Keung, Mr. WANG Bo and Mr. ZHANG Jianhui are independent non-executive Directors.